TY - JOUR AU - Mazzotta, Marco AU - Barba, Maddalena AU - Pizzuti, Laura AU - Vici, Patrizia PY - 2017 TI - Is there a role for adjuvant pertuzumab in HER2-positive breast cancer? JF - Translational Cancer Research; Vol 6, Supplement 7 (October 24, 2017): Translational Cancer Research Y2 - 2017 KW - N2 - The outcomes of human epidermal growth factor receptor 2 (HER2)-positive breast cancer was dramatically changed by the introduction of targeted therapies against the HER2 receptor (1).The monoclonal antibody trastuzumab was the first HER2-directed treatment that demonstrated, together with chemotherapy, a significant improvement in treatment outcomes of this subgroup of patients, both in the metastatic (2) and neo-/adjuvant (3-7) settings, thus becoming the mainstay of treatment in HER2 positive breast cancer. The remarkable results achieved led to the development of additional HER2-targeted drugs, raising the hypothesis of a double-HER2 blockade against breast cancer. UR - https://tcr.amegroups.org/article/view/16369